Insider Trading Activity For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Mitchall G. Clark , EVP of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) reportedly Sold 3,021 shares of the company’s stock at an average price of 14.33 for a total transaction amount of $43,290.93 SEC Form
Insider Trading History For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Analyst Ratings For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
These are 2 Sell Ratings, 3 Buy Ratings .
The current consensus rating for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is Hold (Score: 2.20) with a consensus target price of $25.75 , a potential (88.64% upside)
Analyst Ratings History For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
- On 3/9/2016 J P Morgan Chase & Co Lower Price Target of rating Market Outperform with a price target of $40.00 to $34.00
- On 7/9/2016 JMP Securities Reiterated Rating Buy
- On 9/15/2016 Goldman Sachs Group, Inc. (The) Downgraded rating Neutral to Sell with a price target of $23.00 to $16.00
- On 3/16/2017 Citigroup Inc. Set Price Target of rating Sell with a price target of $10.00
- On 6/22/2017 Jefferies Group LLC Reiterated Rating Buy to Buy with a price target of $30.00
- On 6/26/2017 William Blair Reiterated Rating Outperform
- On 8/7/2017 Canaccord Genuity Set Price Target of rating Buy with a price target of $47.00
Recent Trading Activity for Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Shares of Atara Biotherapeutics, Inc. closed the previous trading session at 13.65 down -0.70 -4.88% with 233,274 shares trading hands.